Campbell & Co Investment Adviser’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,094
| Closed | -$293K | – | 1144 |
|
|
2025
Q3 | $293K | Sell |
2,094
-4,666
| -69% | -$631K | 0.02% | 917 |
|
|
2025
Q2 | $849K | Sell |
6,760
-4,813
| -42% | -$600K | 0.05% | 582 |
|
|
2025
Q1 | $1.58M | Sell |
11,573
-18,936
| -62% | -$2.71M | 0.12% | 261 |
|
|
2024
Q4 | $4.67M | Buy |
30,509
+13,590
| +80% | +$2.29M | 0.36% | 49 |
|
|
2024
Q3 | $3.28M | Buy |
16,919
+14,123
| +505% | +$2.95M | 0.24% | 80 |
|
|
2024
Q2 | $648K | Buy |
+2,796
| New | +$608K | 0.06% | 547 |
|
|
2023
Q4 | – | Sell |
-2,093
| Closed | -$538K | – | 1101 |
|
|
2023
Q3 | $538K | Sell |
2,093
-537
| -20% | -$144K | 0.06% | 484 |
|
|
2023
Q2 | $749K | Buy |
2,630
+1,803
| +218% | +$537K | 0.13% | 252 |
|
|
2023
Q1 | $230K | Sell |
827
-4,848
| -85% | -$1.34M | 0.04% | 697 |
|
|
2022
Q4 | $1.57M | Sell |
5,675
-278
| -5% | -$78.5K | 0.38% | 23 |
|
|
2022
Q3 | $1.59M | Buy |
5,953
+1,752
| +42% | +$372K | 0.36% | 42 |
|
|
2022
Q2 | $857K | Buy |
4,201
+1,209
| +40% | +$247K | 0.23% | 109 |
|
|
2022
Q1 | $630K | Buy |
+2,992
| New | +$651K | 0.17% | 192 |
|
|
2021
Q3 | – | Sell |
-2,600
| Closed | -$900K | – | 593 |
|
|
2021
Q2 | $900K | Buy |
+2,600
| New | +$788K | 0.37% | 58 |
|
|
2020
Q3 | – | Sell |
-1,402
| Closed | -$375K | – | 381 |
|
|
2020
Q2 | $375K | Buy |
+1,402
| New | +$421K | 0.47% | 62 |
|
|
2020
Q1 | – | Sell |
-3,311
| Closed | -$982K | – | 70 |
|
|
2019
Q4 | $982K | Buy |
3,311
+2,162
| +188% | +$600K | 0.3% | 65 |
|
|
2019
Q3 | $268K | Buy |
1,149
+73
| +7% | +$17K | 0.1% | 435 |
|
|
2019
Q2 | $252K | Buy |
+1,076
| New | +$248K | 0.11% | 379 |
|
|
2018
Q4 | – | Sell |
-762
| Closed | -$269K | – | 339 |
|
|
2018
Q3 | $269K | Buy |
+762
| New | +$262K | 0.18% | 261 |
|
|
2018
Q2 | – | Sell |
-762
| Closed | -$209K | – | 382 |
|
|
2018
Q1 | $209K | Buy |
+762
| New | +$237K | 0.18% | 289 |
|
|
2017
Q3 | – | Sell |
-3,490
| Closed | -$947K | – | 354 |
|
|
2017
Q2 | $947K | Buy |
+3,490
| New | +$923K | 0.88% | 7 |
|
|
2014
Q1 | – | Sell |
-4,598
| Closed | -$1.28M | – | 210 |
|
|
2013
Q4 | $1.28M | Buy |
+4,598
| New | +$1.19M | 0.29% | 111 |
|
|
2013
Q3 | – | Sell |
-5,035
| Closed | -$1.08M | – | 244 |
|
|
2013
Q2 | $1.08M | Buy |
+5,035
| New | +$1.08M | 0.21% | 135 |
|
Other funds holding BIIB
Campbell & Co Investment Adviser's BIIB Position: Q4 2025 in Review
Campbell & Co Investment Adviser sold out of Biogen (BIIB) in Q4 2025, closing a stake of 2,094 shares — an estimated $293K sold.
Campbell & Co Investment Adviser first reported a position in BIIB in Q2 2013 and held it in 23 quarters. The position peaked at $4.67M in Q4 2024. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.
- Campbell & Co Investment Adviser reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
- Campbell & Co Investment Adviser sold 2,094 Biogen shares in Q4 2025, an estimated $293K.
- Campbell & Co Investment Adviser first reported a position in Biogen in Q2 2013 and held it in 23 quarters.
- Campbell & Co Investment Adviser's Biogen position peaked at $4.67M in Q4 2024.
- 1,001 funds tracked by Wall St. Rank held Biogen as of Q4 2025.
Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.